Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2008100106 - PRÉPARATION À LIBÉRATION CONTRÔLÉE CONTENANT DU CILOSTAZOL ET SON PROCÉDÉ DE FABRICATION

Numéro de publication WO/2008/100106
Date de publication 21.08.2008
N° de la demande internationale PCT/KR2008/000901
Date du dépôt international 15.02.2008
CIB
A61K 9/10 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
9Préparations médicinales caractérisées par un aspect particulier
10Dispersions; Emulsions
CPC
A61K 31/4709
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4709Non-condensed quinolines and containing further heterocyclic rings
A61K 9/1635
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1605Excipients; Inactive ingredients
1629Organic macromolecular compounds
1635obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
A61K 9/1652
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1605Excipients; Inactive ingredients
1629Organic macromolecular compounds
1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
A61K 9/1694
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1682Processes
1694resulting in granules or microspheres of the matrix type containing more than 5% of excipient
A61K 9/205
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2004Excipients; Inactive ingredients
2022Organic macromolecular compounds
205Polysaccharides, e.g. alginate, gums; Cyclodextrin
A61K 9/2054
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2004Excipients; Inactive ingredients
2022Organic macromolecular compounds
205Polysaccharides, e.g. alginate, gums; Cyclodextrin
2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Déposants
  • AMOREPACIFIC CORPORATION [KR]/[KR] (AllExceptUS)
  • PACIFIC PHARMACEUTICAL CO., LTD. [KR]/[KR] (AllExceptUS)
  • PARK, Jin Woo [KR]/[KR] (UsOnly)
  • SHIN, Kwang Hyun [KR]/[KR] (UsOnly)
  • KWON, Min Jung [KR]/[KR] (UsOnly)
  • BAE, Joon Ho [KR]/[KR] (UsOnly)
  • JEON, Do Yong [KR]/[KR] (UsOnly)
Inventeurs
  • PARK, Jin Woo
  • SHIN, Kwang Hyun
  • KWON, Min Jung
  • BAE, Joon Ho
  • JEON, Do Yong
Mandataires
  • JANG, Seongku
Données relatives à la priorité
10-2007-001635216.02.2007KR
Langue de publication anglais (EN)
Langue de dépôt coréen (KO)
États désignés
Titre
(EN) CONTROLLED RELEASE PREPARATION CONTAINING CILOSTAZOLAND PROCESS FOR THE PREPARATION THEREOF
(FR) PRÉPARATION À LIBÉRATION CONTRÔLÉE CONTENANT DU CILOSTAZOL ET SON PROCÉDÉ DE FABRICATION
Abrégé
(EN)
A controlled release preparation which comprises particles containing cilostazol or its pharmaceutically acceptable salt dispersed in a solubilizing agent and an erodible material encasing said particles which is capable of forming a hydrogel, can maintain a constant level of cilostazol in the blood through its slow release during its prolonged residence time in the stomach and intestines, thereby minimizing adverse effects caused by rapid release of the drug or solubilizing agent.
(FR)
Préparation à libération contrôlée contenant des particules contenant elles-mêmes du cilostazol ou un sel de qualité pharmaceutique de cette susbstance, dispersée dans un agent solubilisant et une matière érodable renfermant lesdites particules. Cette préparation peut former un hydrogel et maintenir un niveau constant de cilostazol dans le sang grâce à sa libération lente pendant un temps de séjour prolongé dans l'estomac et les intestins, ce qui atténue les effets contraires dus à une libération rapide du médicament ou de l'agent solubilisant.
Dernières données bibliographiques dont dispose le Bureau international